OptimAIze: AI-Driven Closed-Loop Platform Aims to Accelerate Antibiotic Development Against Multidrug-Resistant Bacteria
核心洞察
A new collaborative project called OptimAIze has launched to combine generative AI with experimental validation for faster antibiotic candidate identification and optimization.
The project integrates mechanistic knowledge into AI models to improve predictions of antibiotic efficacy and reduce cytotoxicity against human cells.
A novel closed-loop learning cycle enables AI models to suggest new drug candidates, which are then synthesized and tested, with results fed back to continuously improve predictions.
Millions of deaths worldwide are linked to antibiotic resistance each year, yet the development of new antibiotics remains exceptionally risky, with many drug candidates failing in early development phases due to undesirable side effects or lack of efficacy. To address this urgent medical need, the German Research Center for Artificial Intelligence (DFKI (搜索)), Saarland University (搜索), the Helmholtz Institute for Pharmaceutical Research Saarland (搜索) (HIPS), and the biotechnology company smartbax GmbH (搜索) have launched the collaborative project OptimAIze.
The project combines state-of-the-art artificial intelligence methods with innovative biological testing procedures to identify promising antibiotic candidates more quickly and to optimize them in a targeted manner. Funded by the Federal Ministry of Research, Technology, and Space under the funding guideline "Application of Artificial Intelligence in Drug Discovery," OptimAIze is designed as a three-year initiative.
Bridging AI and Mechanistic Expertise
A key challenge in antibiotic development is the high preclinical failure rate, often caused by an unfavorable balance between efficacy and toxicity. OptimAIze directly targets this problem by developing and applying generative AI methods to modify drug candidates, aiming to increase their efficacy while reducing cytotoxicity—the potential damage to human cells.
A particularly innovative aspect of the project is the integration of mechanistic knowledge into the AI models. "Artificial intelligence opens up enormous opportunities for drug discovery. At the same time, purely data-driven models reach their limits, especially when only limited or unbalanced data is available," said Prof. Dr. Verena Wolf, Head of Neuro-Mechanistic Modeling at DFKI (搜索) and Project Coordinator of OptimAIze. "That is why, in OptimAIze, we rely on a combination of AI and mechanistic expertise. This allows us not only to make more precise predictions but also to better understand why certain molecules are effective or toxic."
The Closed-Loop Learning Cycle
At the heart of OptimAIze is a novel closed-loop learning cycle that combines artificial intelligence and experimental validation. High-resolution cytotoxicity data are analyzed using modern AI methods. The models not only learn to predict the efficacy and tolerability of molecules but can also specifically suggest new drug candidates, which are then tested experimentally. The results are fed back into the AI models, continuously improving their predictive power.
The integrated AI optimization combines knowledge across AI and computational chemistry to efficiently propose molecules with improved antibiotic activity and lower toxicity that can be synthesized and tested immediately.
Consortium Expertise
The consortium brings together complementary expertise across the antibiotic development pipeline. DFKI (搜索) develops methods for explainable and generative AI. Saarland University (搜索) contributes expertise in drug design, language models, and single-cell analyses. HIPS handles the chemical synthesis and optimization of the candidates. smartbax GmbH (搜索) provides exclusive data and drug programs from industrial antibiotic research.
Open-Source Commitment
Beyond developing specific antibiotic candidates, OptimAIze aims to make innovative AI methods and software tools available to the scientific community. The algorithms developed will be published as open source—as far as possible—to support further research projects in the long-term fight against antibiotic resistance. The project aspires to set new standards for AI-supported drug discovery and make a significant contribution to combating antimicrobial resistance.